#2

AstraZeneca Docket No. 100829-1P US

## IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Application of:

Peter Bernstein et al.

International Application Number:

PCT/SE2003/001399

International Filing Date:

September 8, 2003

For:

NAPHTHYL ETHER COMPOUNDS AND THEIR USE

Group Art Unit: Not yet allocated

Examiner: Not yet allocated

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit herewith a list of patents and publications which they believe may be material to the patentability of claims of the above-identified application and for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

The references listed on the attached Form PTO/SB/08a and PTO/SB/08b were cited by the Examiner in the International Search Report.

This Information Disclosure Statement is being filed within three months of the filing of the application. Accordingly, no fee is required for consideration of the references filed herewith.

By:

Respectfully submitted,

Dated: March 8, 2005

Kenneth F. Mitchell, Ph.D.

Attorney for Applicants

Reg. No. 42,007 Telephone: 302/886-7466

PTO/SB/08a (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449A/PTO Application Number IA No. PCT/SE2003/01399 Filing Date Intl Filing Date 9/8/2003 INFORMATION DISCLOSURE First Named Inventor Peter BERNSTEIN STATEMENT BY APPLICANT Art Unit **Examiner Name** (Use as many sheets as necessary Attorney Docket Number 100829-1P US

of

Sheet

			U. S. PATENT D	OCUMENTS	
Examiner nitials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2 (if known)</sup>			
	l '	US-			
		US-			
	1	US-			
		US-			
		US-			
	<b>†</b>	US-			
	1 -	US-			
		US-			
	1	US-			
	+-	US-			

FOREIGN PATENT DOCUMENTS										
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>		
		GB	2347423	Α	09/06/2000	Merck Sharp & Dohme				
		wo	9519344	A1	07/20/1995	Merck Snarp & Donne	the claims, pg 18, ln 12 - pg 19, ln 20			
		wo	9410165	A1	05/11/1994	Merck Sharp & Dohme	the claims, pg 20, ln 16 - pg 21, ln 29			
								L		

Examiner Signature	Date Considered	
Signature		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attended. Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## DT15 Rec'd PCT/PTO 0 8 MAR 2005

PTO/SB/08b (08-03) Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	form 1449B/PTO				Complete if Known	10/5272	
				Application Number	IA NO. PCT/SE200	3/001399	
	RMATION D	<del>-</del>		Filing Date	Intl. Filing Ssept. 8, 2003		
STATEMENT BY APPLICANT				First Named Inventor	Peter BERNSTEIN		
				Art Unit			
(Use as many sheets as necessary)				Examiner Name			
Sheet	1	of	1	Attorney Docket Number	100829-1P US		

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>						
		GRAEME I. STEVENSON ET AL, "4,4-Disubstituted Piperidines: A New Class of NK1 Antagonist," J. Med. Chem., Vol. 38 (No. 8), p. 1264-1266, (1995).					
		GRAEME I. STEVENSON ET AL, "4,4 Disubstituted Piperidine High-Affinity NK1, Antagonists: Structure-Activity Relationships and in Vivo Activity," J. Med. Chem., Vol. 41 (No. 23), p. 4623-4635, (November 23, 1998).					
		JASON M. ELLIOTT ET AL, "4,4-Disubstituted Cyclohexylamine NK1 Receptor Antagonists I," Bioorganic & Medicinal Chemistry Letters, Vol. 12 (No. 13), p. 1755-1758, table 3, compound nos. 23, 27 (July 8, 2002).					
		THOMAS RYCKMANS ET AL, "First Dual NK1 Antagonists-Serotonin Reuptake Inhibitors: Synthesis and SAR of a New Class of Potential Antidepressants," Bioorganic & Medicinal Chemistry Letters, Vol. 12 (No. 2), p. 261-264, (2002).					

		<del>                                     </del>
		· ·
Examiner	Date	
	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. Tapplicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.